icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
nQCntEGQZdFLUqhU